ArticleFrontiers in medicine2025
Assessment of extracellular vesicle microRNAs detection in predicting benign and malignant pulmonary ground glass nodules.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess extracellular vesicle microRNAs detection in predicting malignant and benign pulmonary ground glass nodules (GGNs). Methods: A retrospective study was conducted on 96 patients with pulmonary GGNs, hospitalized in Suzhou Kowloon Hospital and The Second Affiliated Hospital of Soochow University, Shanghai Jiaotong University School of Medicine between April 2021 and March 2022. Based on pathological diagnosis, 67 were in the malignant group and 29 in the benign group. Additionally, 50 healthy individuals from the same hospitals were enrolled as controls. Plasma exosomal microRNAs (miRNAs) levels were measured by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) in the three groups. The diagnostic value of candidate miRNAs was analyzed using receiver operating characteristic (ROC) curves. Results: Nodule size and proportion of pure GGNs were significantly higher in the malignant group than the benign group ( Conclusion: miR-1-3p, miR-9-5p, miR-17-5p, miR-20b-5p, and miR-92a-2-5p show promise as diagnostic biomarkers for GGN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.